Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1755-8794
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation ; volume:15 ; number:1 ; day:19 ; month:2 ; year:2022 ; pages:1-7 ; date:12.2022
BMC medical genomics ; 15, Heft 1 (19.2.2022), 1-7, 12.2022
- Urheber
-
Baba, Yuto
Kosaka, Takeo
Kobayashi, Hiroaki
Nakamura, Kohei
Mikami, Shuji
Nishihara, Hiroshi
Nakanishi, Makoto
Oya, Mototsugu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12920-022-01178-z
- URN
-
urn:nbn:de:101:1-2022052220430559846000
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Baba, Yuto
- Kosaka, Takeo
- Kobayashi, Hiroaki
- Nakamura, Kohei
- Mikami, Shuji
- Nishihara, Hiroshi
- Nakanishi, Makoto
- Oya, Mototsugu
- SpringerLink (Online service)
Ähnliche Objekte (12)
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells